Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW Extension Study in Retinopathy of Prematurity (Japan)
jRCT2080223333Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of ranibizumab in retinopathy of prematurity (ROP) (2 arms), sponsored by Novartis. Started Sep 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on jRCT2080223333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223333.